|
Accueil > Actualité
Pfizer: US FDA broadens indication for prostate cancer drug
(CercleFinance.com) - Pfizer's Xtandi drug won approval from U.
S. regulators for patients with non-metastatic castration-resistant prostate cancer, the biopharmaceutical company said on Friday. The Food and Drug Administration had granted a priority review designation to the drug for this indication, based on positive results from a Phase 3 trial. The FDA action broadens the indication for Xtandi, making it the first and only oral medication FDA-approved for both non-metastatic and metastatic castration-resistant prostate cancer. Xtandi was first approved by the FDA in 2012. Copyright (c) 2018 CercleFinance.com. All rights reserved. |
19/04/2024 18:06
Alstoma conclu un accord avec Knorr-Bremse 19/04/2024 17:30 Danoneen hausse après deux analyses positives 19/04/2024 16:35 TotalEnergiespartenariat avec OK Petroleum aux USA 19/04/2024 16:29 BAE Systemsmodernise une usine de munitions 19/04/2024 16:15 Netflixle titre trébuche après une publication contrastée 19/04/2024 16:09 Bayersigne un contrat de fourniture d'énergie renouvelables Tous les articles sociétés |
